AI in drug discovery — what it is, where we stand and the path forward
Summary
This article provides an overview of AI in drug discovery, discussing its current applications and future directions.
View Cached Full Text
Cached at: 08/15/26, 09:38 PM
Similar Articles
Article: 'Artificial intelligence in drug discovery — what it is, where we stand and the path forward'
A Nature Reviews Drug Discovery perspective critically reviews AI in drug discovery, noting limited clinical impact and offering recommendations for improving translational relevance.
AI is accelerating drug development
AI is transforming U.S. pharmaceutical R&D by accelerating drug discovery, preclinical testing, clinical trials, and regulatory review, with early evidence suggesting it could cut development times by roughly half and reduce costs.
Closing the data loop in AI-driven drug discovery
AI accelerates drug discovery by predicting candidates and reducing costs, but success depends on high-quality data and integration with lab systems to close the data loop and validate predictions.
What AI x Biology developments should we be watching?
The article discusses and seeks insights on upcoming AI applications in biology, including labs, startups, and projects that could yield tangible results in areas like supplement optimization and bioactive compounds.
How AI helps scientists design the next generation of medicines
AI is accelerating biologic drug design by predicting candidate molecules and enabling multi-target therapies, with potential to cut discovery timelines by 50% and target previously undruggable diseases.